(1) that the mortality rate before enucleation is low, (2) that the mortality rate rises abruptly following enucleation, (3) that approximately two-thirds of the fatalities could be attributed to the dissemination of tumour emboli at the time of enucleation.3
Since the earliest descriptions of pigmented tumours at the beginning of the 19th century,1 and of ocular tumours of this nature in particular, controversy has existed as to the histogenesis, behaviour, clinical course, and treatment of choroidal malignant melanoma. The most recent of these disputes has been that arising from the publications by Zimmerman and colleagues.2-These writers having initially stated that 'It cannot be concluded that there is a group of favourable cases (of malignant choroidal melanoma) for which enucleation is excessive treatment'. Then in a later article they looked again at the data of Paul et al. 5 From this new analysis they arrived at certain impressions: (1) that the mortality rate before enucleation is low, (2) that the mortality rate rises abruptly following enucleation, (3) that approximately two-thirds of the fatalities could be attributed to the dissemination of tumour emboli at the time of enucleation.3
In a subsequent article' these writers expanded on the evidence to support these postulates.
As part of a study6 of a large series of choroidal malignant melanomas which was under way at the Institute of Ophthalmology at this time I subjected our available data to a more exhaustive examination of mortality patterns. This was in an attempt to throw further light if possible on this matter. New material will also be presented here in relation to the type of treatment used and its effect on mortality. 
Material and methods
The cases of malignant melanoma of the choroid on which this study was based were those seen and treated at Moorfields Eye Hospital between 1949 and 1972. By not including any more recent cases a minimum period of 5 years' follow-up was possible. This follow-up was carried out at Moorfields Eye Hospital at the City Road or High Holborn Branches, or by the referring hospital, or, finally, by letter via the patient's general practitioner. In those cases that died the cause of death was either discovered directly from the Cancer Registry at the Institute of Ophthalmology following notification by the hospital or general practitioner concerned, or in some cases a relative supplied notification of death and later the cause was sought from the Registrar General's records. All available information regarding the patients was stored in the card index of the Cancer Registry at the Institute of Ophthalmology.
In cases where the information was incomplete with regard to such things as length of history prior to treatment the patient's notes were obtained from the files at Moorfields Eye Hospital. By far the largest part of the series consisted of patients who had been treated by enucleation as a primary procedure. The total number of cases was 578, of whom 506 had had enucleation. Of these 506 patients 484 had their enucleations as a primary procedure, and 22 patients initially treated conservatively had either had continued tumour growth or complications from their treatment which had made enu-565 cleation necessary. As well as using the information obtained as above, the slides from the specimens obtained from these cases were examined to determine various pathological parameters which will be mentioned shortly. Between Of the group III patients, only 2 patients were observed with no treatment mode being employed, both of these patients died-one of unrelated causes and one who had presented with established melanoma metastatic disease died from these metastases. There were 2 other patients in the series as a whole who had established metastatic disease with a choroidal melanoma as the assumed primary at the time of diagnosis.
PROGNOSIS
Although as part of the doctoral thesis on which this paper is based prognosis was assessed by both cross-tabulations of risk factors in a single and multiple variate manner, the results were considered not as useful as those obtained by the use of actuarial life tables, and these alone will be presented here. This method allowed for the cases being withdrawn because of death from other causes and also for patients who were not followed up for the whole period under review to be included. This actuarial method of assessing outcome was also used by Shammas and Blodi.9 It has the added value of providing not only figures for survivors but also the chances of a patient dying in any given year following primary treatment. Using this method also will avoid any criticisms of the sort levelled by Siegel et al.13 at Zimmerman and McLean4 for their use of statistics from Paul et al. 6 Whole series. With the use of life tables as shown in Table 1 the series as a whole was assessed. The actuarial survival curves will be considered first. It will be seen from the graph (Fig. 1) that the overall survival rates were 78-7% at 5 years, 66-2% at 10 years, and 61% at 15 years. This is somewhat better than the figures of Paul et al.5 who used an actuarial method of calculating their results (71% at 5 years, 60% at 10 years, and 46% at 15 years). It will be seen when Fig. 1 is considered also that the nonenucleated group fared rather better than the enucleated group. The reasons for this will be discussed below.
Sex. There was a small survival difference between the sexes in that males seemed to survive better (at 10 years, males 69-2% and females 62-2% survival) than the females. There is no very ready explanation for this except possibly the higher incidence of heavy pigmentation in the older females. No (Fig. 3) shows the dramatic difference between these 3 groups.
Position of anterior border. If the position of the anterior border is divided simply into those with this border in front of and those behind the equator, there is a striking difference in survival. At Reticulin fibre content. In my thesis6 I found that for various risk factors there were no useful correlations for reticulin content. Indeed for prognosis an entirely different result from that found in other series is demonstrated with no reticulin (83-6% survival) given a better prognosis than heavy reticulin (53 9% survival) at 10 years. However, as will be seen later in the discriminant analysis, reticulin is not useful as a prognostic factor.
Scleral extension. This factor shows a marked difference between the increasing degrees of scleral extension (Fig. 5) . Survival for those patients with no extension is really quite good (89-7% at 5 years, 81-7% at 10 years, and 76A4% at 15 years) as compared to patients with episcleral extension (42 3% at 5 years, 23-8% at 10 years, and 21-4% at 15 years). In fact all those patients who will die from their tumour are dead within 11 years of primary treatment where episcleral extension is present. A series of life tables were then constructed and graphs drawn from these to assess the influence of more than one factor on prognosis at any one time. Firstly age, either under or over 60 years at the time of primary treatment, was considered in relation to size, cell type, the presence of heavy pigment, and the presence of episcleral extension.
Age and size. The size of the tumour for the purposes of analysis here was recorded as being either less than or greater than 10 mm largest tumour diameter. When these 2 groups are combined with the 2 age groups plotted on a graph survival of both small tumour groups was very similar (83-5% at 10 years for the under 60s and 81 5% for the over 60s). The large tumour groups, however, had as expected a much worse prognosis, and the older patients of these 2 did the worst (54 3% survival at 10 years for the under 60s, 42-2% for the over 60s).
Age and cell type. A similar situation was found when cell type and age were considered in relation to prognosis in that spindle cell tumours in both age groups do quite well (at 10 years under 60s 76-4% survival, over 60s 69 4%) and mixed and epithelioid tumours (considered as one group) do considerably worse with the older patients surviving least well (at 10 years under 60s 49 9% survival, over 60s 24*4%).
Age and heavy pigment content. In this instance the difference between the age groups is quite large though in both the prognosis is poor (at 10 years, 47-5% survival for the under 60s and 27-0% survival for the over 60s).
Age and episcleral extension. All patients, as has been shown, have poor prognosis in this group, and the difference in survival seems unrelated to age, being at 10 years 23% for under 60s and 24% for over 60s.
State of Bruch's membrane. The state of Bruch's membrane when considered in isolation appears to have a profound effect on prognosis, i.e., at 10 years survival of 80-8% for those patients with an intact membrane and 55-8% where it is ruptured. In fact if the relationship of size to the state of Bruch's membrane is remembered, then the survival figures are almost certainly a function of the difference in size of the 2 tumour groups, Bruch's membrane intact and ruptured.
Next, size in the 2 groups as already mentioned and the variable cell type, presence of heavy pigmentation, and presence of episcleral extension were related in a life table and graphical form.
Size and cell type. In this combination it can be seen that, although size is very important within the different cell types themselves, mixed cell and epithelioid tumours have a worse prognosis than those with predominantly spindle cells. It is interesting that the larger spindle cell tumours and the smaller mixed cell tumours have an almost identical prognosis (Fig. 6 ).
Size and heavy pigment. Size showed itself to be important when taken with heavy pigment in that smaller tumours had a much better prognosis, i.e., 61% survival at 10 years as opposed to 27% for the larger tumours.
Size and episcleral extension. There was no such obvious difference between the size groups here, though whether this is a true relationship is uncertain because of the small numbers involved in the small size group with episcleral extension. During the period that the doctoral thesis on which this study is based6 was being compiled, the ideas of Zimmerman et Accordingly graphs were drawn from the life tables used to calculate the survival data. This was done not only for the series as a whole, but also for various single and combinations of risk factors thus allowing a closer assessment of the influence of these factors on the time course of prognosis.
In the first graph ( Fig. 7) is recorded the annual likelihood of mortality for the whole series, enucleated patients and those treated by conservative means.
Considering the whole series in the first instance, there would appear to be 2 peaks in mortality-one at 3-4 years following treatment and the other at 9-10 years. A similar shaped graph is obtained from those patients undergoing enucleation, but for the patients treated conservatively a much less definite pattern is seen. Although Zimmerman et al.4 chose to ignore the second peak, it is present on their graph and also that of Benjamin et al."1 and Jensen.'2 The significance of the second peak will be discussed below.
The following risk factors were analysed individually to assist the influence on mortality rates which they might have and to demonstrate the (Figs. 8, 9, 10, 11, 12, 13) .
The duration of history was for those patients with histories less than or more than 1 be seen the mortality peak occurred 1 year earlier in those patients with the longer history. This was probably related to the patient's age more than anything else, because we know that the over 60s tend to have longer histories and they also have an earlier mortality peak.
Tumours with anteriorly placed borders have a much more dramatic mortality pattern than those with this border posterior to the equator (Fig. 9) . In fact the pattern for these posterior tumours was very similar to that for small tumours (Fig. 10 ) spindle cell tumours (Fig. 11) and tumours with no extension (Fig. 12) , also with the tumours treated by conservative means. This similarity is not surprising, as small tumours tend to be spindle celled, posteriorly placed, with less extension, and are more likely to be the type treated conservatively. 6 The dramatic rises in probability of death particularly seen for large tumours, those with epithelioid cells present, and those which have their sclera excessively invaded or perforated speak for themselves by comparison. The factors which may influence these graphs will be discussed below. YEARS FOLLOWING TREATMENT Fig. 11 Probability graph for death from choroidal malignant melanoma for cell type.
In order to assist further in the assessment of individual cases a discriminative analysis was carried out. Initially this was done in the linear manner suggested by McLean et al.2 However, it was felt that cell type could not truly be assessed in such a manner as it implied that spindle cell tumours were necessarily of better prognosis than epithelioid tumours and mixed cell tumours somewhere in between. To give a more accurate picture the 3 cell types were assessed in this manner separately. Certain risk factors, notably pigment, were found to have a different influence in different cell type tumours. McLean et al.2 felt that this finding in spindle cell tumours was due to misclassification of some of these tumours, which were really mixed cell type masked by pigment. However, if this were true, any prognostic value of pigmentation would be weakened in their analysis by the fact that mixed and spindle cell tumours were being considered together.
The results shown in Table 2 of the stepwise discriminant analysis suggest that the most important predictor for outcome is pigmentation in spindle One similarity which should also be mentioned is between the 10-year survival in small enucleated tumours and those treated conservatively (81 4% for small tumours, 81 3% for conservatively treated tumours). This would suggest that enucleation need have little place in the treatment of such tumours as a primary procedure while good vision may be maintained; also that there is no greater likelihood of tumour spread than if the tumour is removed completely. As will be seen when the rates of mortality in other groups are considered in relation to enucleation, no such comforting picture may be said to exist in these other cases.
While reviewing the work of Paul et al. figures, the majority of the tumours which they cite either have no peak or have their highest mortality in the first post-treatment year, with death falling away in later years. Only in melanoma of the skin and breast carcinoma with regional involvement of the surgically treated cases and carcinoma of the cervix treated by irradiation is any similarity of pattern seen. We are not told whether the irradiation was administered by local insertion of radioactive materials in the patients with cervical carcinoma, which, if this were the case, would necessitate some local manipulation of the tumour.
The explanation of the second peak was at first hard to realise. It was possible that immunological factors were important, such that in those patients dying in the earlier peak they might be less able to cope with any outflow of metastatic cells from the 
